SUNRISE-CRC: a randomized phase II study of high-dose intermittent sunitinib versus trifluridine/tipiracil in metastatic colorectal carcinoma
The Oncologist · 2025
DOI: 10.1093/oncolo/oyaf288 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift The Oncologist, 2025. Verfasst von Jorien B E Janssen und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Research Institute for Medical Innovation, Radboud University Medical Centre, Nijmegen 6525GA, The Netherlands. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Colorectal Neoplasms, Pyrrolidines, Sunitinib. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: ZonMw.
Abstract (Originalsprache)
Background
Patients with metastatic colorectal cancer often have poor or short responses to currently available therapies. Drug repurposing with alternative dosing schedules may offer unexpected clinical benefit, even for agents that previously failed for this indication.
Methods
We explored a high-dose treatment strategy for sunitinib, assessing its potential for both cancer cell killing and inducing immunogenic cell death in patient-derived tumor organoids (PDTOs) of metastatic colorectal cancer (mCRC). In a randomized clinical trial, we studied the efficacy of high-dose intermittent sunitinib (700 mg once every 2 weeks) in patients with advanced CRC compared to standard therapy with trifluridine/tipiracil. The primary outcome measure was progression-free survival (PFS); secondary outcomes included overall survival, safety and tolerability, quality of life, and exploratory biomarker analyses.
Results
While high, intermittent dosing was found to effectively kill PDTOs in vitro, no support for immunogenic cell death was found. In our clinical trial, among a total of 63 evaluable patients, median PFS was 2.8 months (95% CI 0.9-4.7) for the investigation arm compared to 1.9 months (95% CI 1.6-2.3) for the trifluridine/tipiracil group (P = .78, HR 1.22; 95% CI 0.73-2.04). The trial was halted prematurely due to toxicities: in particular, hemorrhage, fever and gastrointestinal adverse events.
Conclusion
High-dose intermittent sunitinib treatment did not improve PFS for patients with heavily pretreated mCRC compared to standard 3rd or 4th-line treatment with trifluridine/tipiracil, whereas significant toxicity was observed. In addition, this approach provoked no relevant immunological responses in vitro, discouraging further research for potential combinations with immunotherapeutics. Identifier NCT03909724
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Research Institute for Medical Innovation, Radboud University Medical Centre, Nijmegen 6525GA, The Netherlands.
- Department of Medical Biosciences, Research Institute for Medical Innovation, Radboud University Medical Centre, Nijmegen 6525GA, The Netherlands.
- Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Centre Rotterdam, Rotterdarm 3015GD, The Netherlands.
- Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam 1081HV, The Netherlands.
- Department of Medical Oncology, Jeroen Bosch Hospital, 's-Hertogenbosch, 5223GZ The Netherlands.
- Department of Gastroenterology, Netherlands Cancer Institute, Amsterdam, 1066CX The Netherlands.
ORCID-Profile: Jorien B E Janssen, Kirti K Iyer, Sophie L Gerritse, Eline Janssen, Elske C Gootjes, Mariette Labots, Tineke E Buffart, Laurien M Buffart, Marianne A Jonker, Erik van den Hombergh, Nielka P van Erp, Jan Paul Medema, Daniele V F Tauriello, Dennis Poel, Henk M W Verheul
Förderung
- ZonMw
Zitieren
APA
Janssen, J. B. E., Iyer, K. K., Gerritse, S. L., Janssen, E., Gootjes, E. C., Labots, M., Buffart, T. E., Wumkes, M. L., Douma, J. A. J., Streppel, M. M., Buffart, L. M., Jonker, M. A., van den Hombergh, E., van Erp, N. P., Medema, J. P., Tauriello, D. V. F., Poel, D., & Verheul, H. M. W. (2025). SUNRISE-CRC: a randomized phase II study of high-dose intermittent sunitinib versus trifluridine/tipiracil in metastatic colorectal carcinoma. The Oncologist. https://doi.org/10.1093/oncolo/oyaf288
Vancouver
Janssen JBE, Iyer KK, Gerritse SL, Janssen E, Gootjes EC, Labots M, et al. SUNRISE-CRC: a randomized phase II study of high-dose intermittent sunitinib versus trifluridine/tipiracil in metastatic colorectal carcinoma. The Oncologist. 2025. doi:10.1093/oncolo/oyaf288
BibTeX
@article{Janssen2025,
author = {Janssen, Jorien B E and Iyer, Kirti K and Gerritse, Sophie L and Janssen, Eline and Gootjes, Elske C and Labots, Mariette and Buffart, Tineke E and Wumkes, Miriam L and Douma, Joeri A J and Streppel, Mirte M and Buffart, Laurien M and Jonker, Marianne A and van den Hombergh, Erik and van Erp, Nielka P and Medema, Jan Paul and Tauriello, Daniele V F and Poel, Dennis and Verheul, Henk M W},
title = {SUNRISE-CRC: a randomized phase II study of high-dose intermittent sunitinib versus trifluridine/tipiracil in metastatic colorectal carcinoma},
journal = {The Oncologist},
year = {2025},
doi = {10.1093/oncolo/oyaf288}
}
EUVIMED